trending Market Intelligence /marketintelligence/en/news-insights/trending/IQaRHkWxT8Q_aV5-dujWgQ2 content esgSubNav
In This List

Antares Pharma adds Cerecor CEO to board

Blog

Baird Research is Now Exclusively Available in S&P Global’s Aftermarket Research Collection

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity


Antares Pharma adds Cerecor CEO to board

Antares Pharma Inc. said it appointed Cerecor Inc. Peter Greenleaf to its board.

Greenleaf also serves as chairman of BioDelivery Sciences International Inc.'s board, and is a director of Eyetech Pharmaceuticals. His previous roles include chairman and CEO of Sucampo Pharmaceuticals Inc., now owned by Mallinckrodt Public Ltd. Co., and president of MedImmune LLC and MedImmune Ventures Inc., the biologics arm and venture capital arm, respectively, of AstraZeneca PLC.

Ewing, N.J.-based Antares Pharma is a specialty pharmaceutical company that develops and sells self-administered parenteral pharmaceutical products and technologies worldwide.